$497 Million is the total value of MPM BioImpact LLC's 34 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 54.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | $82,295,364 | +5.2% | 7,648,268 | 0.0% | 16.57% | -18.5% | |
| ISEE | Buy | Iveric Bio Inc | $47,784,803 | +87.8% | 1,214,662 | +16.2% | 9.62% | +45.6% |
| KDNY | Buy | Chinook Therapeutics, Inc. | $38,550,859 | +741.9% | 1,003,406 | +407.3% | 7.76% | +552.4% |
| GERN | Buy | Geron Corporation | $29,504,041 | +61.8% | 9,191,290 | +9.4% | 5.94% | +25.4% |
| RETA | Buy | Reata Pharmaceuticals, Inc. | $23,907,377 | +44.5% | 234,478 | +32.6% | 4.81% | +12.0% |
| ITOS | iTeos Therapeutics, Inc. | $23,116,285 | -2.7% | 1,745,943 | 0.0% | 4.66% | -24.6% | |
| NTLA | Sell | Intellia Therapeutics, Inc. | $22,210,378 | +4.1% | 544,639 | -4.9% | 4.47% | -19.3% |
| IOVA | Buy | Iovance Biotherapeutics Inc | $20,768,831 | +30.0% | 2,950,118 | +12.8% | 4.18% | +0.7% |
| RPTX | Repare Therapeutics, Inc. | $17,349,602 | +7.5% | 1,639,849 | 0.0% | 3.49% | -16.7% | |
| RLAY | Buy | Relay Therapeutics Inc. | $17,010,862 | -15.7% | 1,354,368 | +10.5% | 3.42% | -34.7% |
| VERV | Buy | Verve Therapeutics, Inc | $16,086,375 | +38.8% | 857,940 | +6.8% | 3.24% | +7.6% |
| New | Moonlake Immunotherapeutics | $15,050,661 | – | 295,111 | +100.0% | 3.03% | – | |
| RGNX | Buy | REGENXBIO Inc. | $13,127,793 | +12.4% | 656,718 | +6.3% | 2.64% | -12.9% |
| KRTX | New | Karuna Therapeutics Inc | $11,579,573 | – | 53,399 | +100.0% | 2.33% | – |
| INSM | Buy | Insmed Incorporated | $11,177,577 | +64.2% | 529,743 | +32.7% | 2.25% | +27.3% |
| New | Xeris Biopharma Holdings Inc | $10,414,497 | – | 3,974,999 | +100.0% | 2.10% | – | |
| MDGL | Buy | Madrigal Pharmaceuticals inc | $8,780,541 | +0.6% | 38,011 | +5.5% | 1.77% | -22.0% |
| CRNX | Buy | Crinetics Pharmaceuticals Inc. | $8,632,535 | +49.1% | 479,053 | +32.9% | 1.74% | +15.6% |
| TVTX | Buy | Travere Therapeutics Inc. | $8,491,715 | +20.4% | 552,846 | +76.3% | 1.71% | -6.7% |
| RVMD | Buy | Revolution Medicines, Inc. | $7,313,664 | +36.7% | 273,408 | +10.7% | 1.47% | +6.0% |
| HOWL | Werewolf Therapeutics, Inc. | $7,283,434 | +17.3% | 2,388,011 | 0.0% | 1.47% | -9.1% | |
| KALV | New | Kalvista Pharmaceuticals Inc | $6,853,842 | – | 761,538 | +100.0% | 1.38% | – |
| AXSM | Buy | Axsome Therapeutics, Inc. | $6,725,090 | +54.9% | 93,586 | +32.9% | 1.35% | +20.0% |
| FOLD | Buy | Amicus Therapeutics Inc. | $6,482,706 | +50.5% | 516,139 | +32.9% | 1.30% | +16.6% |
| AVDL | New | Avadel Pharmaceuticals PLCsponsored adr | $6,344,635 | – | 384,990 | +100.0% | 1.28% | – |
| VRDN | New | Viridian Therapeutics Inc | $6,074,134 | – | 255,323 | +100.0% | 1.22% | – |
| EWTX | New | Edgewise Therapeutics Inc | $5,524,185 | – | 712,798 | +100.0% | 1.11% | – |
| ADAP | New | Adaptimmune Therapeutics plc | $4,713,719 | – | 5,095,912 | +100.0% | 0.95% | – |
| OLMA | New | Olema Pharmaceuticals, Inc. | $4,176,375 | – | 462,500 | +100.0% | 0.84% | – |
| PHAT | Buy | Phathom Pharmaceuticals inc | $4,042,994 | +166.3% | 282,332 | +32.8% | 0.81% | +106.6% |
| HARP | Harpoon Therapeutics, Inc. | $2,269,662 | -4.6% | 3,196,707 | 0.0% | 0.46% | -26.1% | |
| INZY | Buy | Inozyme Pharma Inc. | $1,820,950 | +36.0% | 326,921 | +39.9% | 0.37% | +5.5% |
| New | Ventyx Biosciences Inc | $1,041,302 | – | 31,747 | +100.0% | 0.21% | – | |
| ONCR | Oncorus, Inc. | $96,270 | -88.2% | 2,377,031 | 0.0% | 0.02% | -91.0% | |
| BDTX | Exit | Black Diamond Therapeutics, Inc. | $0 | – | -144,888 | -100.0% | -0.07% | – |
| AVRO | Exit | AVROBIO, Inc. | $0 | – | -647,918 | -100.0% | -0.17% | – |
| ARQT | Exit | Arcutis Biotherapeutics inc | $0 | – | -254,137 | -100.0% | -0.73% | – |
| TCRR | Exit | TCR2 Therapeutics, Inc. | $0 | – | -3,370,982 | -100.0% | -1.31% | – |
| QURE | Exit | Uniqure N.V. | $0 | – | -348,224 | -100.0% | -1.82% | – |
| INBX | Exit | Inhibrx, Inc Com | $0 | – | -1,192,281 | -100.0% | -5.84% | – |
| PRVB | Exit | Provention Bio Inc | $0 | – | -1,173,809 | -100.0% | -7.35% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.